Article
Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML.
Blood cancer journal - 4 Jan 2023
Tsai Xavier Cheng-Hong, Sun Kuo-Jui, Lo Min-Yen, Tien Feng-Ming, Kuo Yuan-Yeh, Tseng Mei-Hsuan, Peng Yen-Ling, Chuang Yi-Kuang, Ko Bor-Sheng, Tang Jih-Luh, Sun Hsun-I, Liu Ming-Chih, Liu Chia-Wen, Lin Chien-Chin, Yao Ming, Chou Wen-Chien, Hou Hsin-An, Tien Hwei-Fang
Abstract excerpt
A set of myelodysplasia-related (MDS-R) gene mutations are incorporated into the 2022 European LeukemiaNet risk classification as adverse genetic factors for acute myeloid leukemia (AML) based on their poor prognostic impact on older patients. The impact of these mutations on younger patients (age < 60 years) remains elusive. In the study of 1213 patients with de novo non-M3 AML, we identified MDS-R mutations in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.